Clarithromycin inhibits overproduction of muc5ac core protein in murine model of diffuse panbronchiolitis

Yukihiro Kaneko1, Katsunori Yanagihara, Masafumi Seki

  • 1The Second Dept. of Internal Medicine, Nagasaki Univ. School of Medicine, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan.

Insights

Macrolide antibiotics like clarithromycin reduce MUC5AC protein in diffuse panbronchiolitis (DPB) models. This study shows clarithromycin inhibits mucin overproduction, potentially explaining its therapeutic effects in DPB.

Area of Science:

  • Pulmonary Medicine
  • Microbiology
  • Cellular Biology

Background:

  • Diffuse panbronchiolitis (DPB) is often treated with macrolide antibiotics.
  • Hypersecretion is a key feature of DPB, and macrolides are known to inhibit mucin production, but the mechanism is unclear.

Purpose of the Study:

  • To investigate MUC5AC core protein production in a mouse model of DPB.
  • To determine the effect of clarithromycin on MUC5AC production and related signaling pathways.

Main Methods:

  • A mouse model of DPB was established using Pseudomonas aeruginosa infection.
  • Alcian blue-periodic acid-Schiff staining, Western blotting, and analysis of mitogen-activated protein kinase (MAPK) signaling were performed.
  • Mice were treated with clarithromycin.

Main Results:

  • Pseudomonas aeruginosa infection led to increased MUC5AC glycoprotein expression at both mRNA and protein levels.
  • Clarithromycin treatment significantly reduced MUC5AC expression.
  • Extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation, a MAPK pathway component, increased with infection and decreased with clarithromycin treatment.

Conclusions:

  • MUC5AC overproduction is implicated in DPB pathogenesis.
  • Macrolide therapy, such as clarithromycin, may exert clinical benefits by inhibiting mucin overproduction.
  • Modulation of intracellular signaling pathways, including MAPK, is involved in the mechanism of macrolide action in DPB.